Summary

Overview
The Global Bronchiolitis Obliterans Syndrome Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
Bronchiolitis obliterans syndrome (BOS) develops by following a lung transplant or a hematopoietic stem cell transplant (HSCT). A form of obstructive lung illness that affects the tiny airways is bronchiolitis obliterans. It is a rare condition with fibrosis of the terminal and distal bronchioles as well as airflow obstruction as shown by spirometry. It typically has mixed results and causes a steady deterioration in lung function.
A better understanding of the condition has resulted from ongoing research into the pathogenesis and treatment of BOS, which may eventually lead to the creation of more efficient treatments. The prevalence of different lung illnesses and the requirement for lung transplantation are anticipated to rise as the world's population ages. This generational change is a factor in the rise in demand for BOS therapies.
Market Dynamics: Drivers
The Increasing Focus on Bronchiolitis Obliterans Syndrome
The most effective treatment for people with end-stage lung illness is a lung transplant. The median survival after a lung transplant has increased to 6.9 years due to the effectiveness of prophylaxis, new medications, and better risk classification. However, between 30 days and a year after transplant, graft failure accounts for 22.7% of fatalities.
According to Transplantation and Cellular Therapy in 2022, after allogeneic hematopoietic cell transplantation, BOS occurs between 3% and 9% of individuals. The probability of non-relapse mortality (NRM) is higher in patients with moderate or severe lung involvement at the time of chronic graft versus host disease diagnosis (cGVHD) than it is in individuals with mild or no lung involvement, despite the fact that the lung is less frequently affected by cGVHD than other organs.
Limited Treatment Options
BOS is still a difficult disorder to manage, and there is no known cure. The market may be significantly constrained by the scarcity of efficient treatments. Lung transplantation, one of the most definitive treatments for advanced BOS, is a costly procedure. The cost of various pharmaceutical therapies might also be prohibitive for patients and healthcare systems. Long-term immunosuppressive drug use, a typical BOS treatment, can have negative consequences and raise the risk of infections and other complications.
Segment Analysis
The global bronchiolitis obliterans syndrome treatment market is segmented based on drug type, end-user and region.
The immunosuppressive drugs segment accounted for approximately 37.5% of the market share
Chronic inflammation in the transplanted lung's tiny airways is linked to BOS. Drugs that suppress the immune system assist in reducing this inflammation, which can decrease the development of BOS. Corticosteroids (like prednisone), calcineurin inhibitors (like tacrolimus or cyclosporine), and antimetabolites (like mycophenolate mofetil) are often prescribed immunosuppressive medications.
BOS, also known as chronic lung allograft dysfunction (CLAD), is a complication of chronic rejection, which can occur after lung transplantation. Immunosuppressive medications are frequently provided to patients in order to prevent rejection of the transplanted lung. Immunosuppressive medications reduce the likelihood of acute cellular rejection by inhibiting the recipient's immune system's reaction to the transplanted lung tissue.
Geographical Analysis
North America segment accounted for approximately 42.4% of the market share
North America has been a dominant force in the global bronchiolitis obliterans syndrome treatment market. The active major players are driving market in the region. For instance, in May 2023, Zambon, a multinational pharmaceutical company reported the 2023 Virtual International Society for the Pharmacists will feature data from a health economic outcomes study characterizing the lifetime burden of illness for U.S. patients diagnosed with bronchiolitis obliterans syndrome (BOS) following hematopoietic stem cell transplantation (HSCT) or lung transplantation.
Adult BOS patients undergoing a single lung transplant (SLT), double lung transplant (DLT), or an HSCT (rapid decliners) were included in the study. Based on a de-novo six-state natural history model, five of which are defined by stages of chronic lung allograft failure and re-treatment by lung transplant, the assessment examined the estimated lifetime economic burden of illness for BOS patients from the date of diagnosis through end-of-life. Estimates of rates and survival were made from published research and clinical data. A preliminary examination of commercial claims data was used to determine the monthly expenditures associated with using medical resources, using medications, and other related factors.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global bronchiolitis obliterans syndrome treatment market. Clinical studies and BOS therapy research were hampered by the pandemic. Due to limitations on patient recruitment, limited access to medical facilities, and the importance of COVID-19 research, many trials were suspended or delayed. During the pandemic, it was difficult for many people with chronic respiratory illnesses, particularly those who were at risk of getting BOS, to get access to medical care. For some patients, this resulted in delayed diagnoses and therapies.
By Drug Type
• Immunosuppressive Drugs
• Biologics
• Antibiotics
• Others
By End-user
• Hospitals
• Specialty Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Zambon, Incyte Corporation, Genentech and others.
Why Purchase the Report?
• To visualize the global bronchiolitis obliterans syndrome treatment market segmentation based on drug type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of bronchiolitis obliterans syndrome treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global bronchiolitis obliterans syndrome treatment market report would provide approximately 46 tables, 53 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by End-User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Increasing Focus on Bronchiolitis Obliterans Syndrome
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Limited Treatment Options
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. SWOT Analysis
5.7. Patent Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Immunosuppressive Drugs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Biologics
7.4. Antibiotics
7.5. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Zambon*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Incyte Corporation
11.3. Genentech
11.4. XX
11.5. XX
11.6. XX
11.7. XX
11.8. Others
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us